Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Randomised, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU

NCT02998996 is registered in ClinicalTrials.gov with Eurocine Vaccines AB as lead sponsor.

NCT NCT02998996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02998996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Randomised, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU
Lead sponsor
Eurocine Vaccines AB
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2016
Completion date
June 1, 2017
Enrollment
162 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, human